Needham Maintains Buy on Clearside Biomedical, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has maintained a Buy rating on Clearside Biomedical (NASDAQ:CLSD) and raised the price target from $4 to $6.
October 10, 2024 | 9:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has maintained a Buy rating on Clearside Biomedical and increased the price target from $4 to $6, indicating a positive outlook.
The increase in price target from $4 to $6 by Needham suggests a positive outlook for Clearside Biomedical, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100